REGULATED PRESS RELEASE published on 05/23/2025 at 07:30, 1 year 1 month ago Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafonnée à 3 millions d’euros NFL Biosciences annonce une levée de fonds réussie de 3 millions d'euros pour financer son candidat médicament contre l'addiction au tabac. Allocation des fonds pour une étude de Phase 3 de NFL-101 NFL Biosciences NFL-101 Levée De Fonds Phase 3 Addiction Au Tabac
BRIEF published on 05/22/2025 at 17:50, 1 year 1 month ago NFL Biosciences Announces €2.2 Million Capital Increase NFL Biosciences Clinical Trials Capital Increase Biopharmaceuticals Investment Risks
BRIEF published on 05/22/2025 at 17:50, 1 year 1 month ago NFL Biosciences annonce une levée de fonds de 2,2 millions d'euros Augmentation De Capital NFL-101 Levée De Fonds Phase 3 Plateforme PrimaryBid
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 1 year 1 month ago NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voie d’augmentations de capital NFL Biosciences lance une levée de fonds de 2,2 millions d'euros pour étude sur le traitement des addictions avec nouveau médicament NFL-101 NFL Biosciences NFL-101 Levée De Fonds Addictions Étude Phase 3
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 1 year 1 month ago NFL Biosciences launches a capital increase of approximately €2.2 million NFL Biosciences launches a €2.2 million capital increase through global offering for smoking cessation drug development. Subscription price: €1.20/share NFL Biosciences Capital Increase Smoking Cessation Subscription Price Global Offering
BRIEF published on 05/21/2025 at 17:50, 1 year 2 months ago Résultats de l'Assemblée Générale de NFL Biosciences NFL Biosciences Actionnaires Assemblée Générale Biopharmaceutique Resolutions
BRIEF published on 05/21/2025 at 17:50, 1 year 2 months ago NFL Biosciences General Meeting Results NFL Biosciences Shareholders Biopharmaceuticals Resolutions General Assembly
REGULATED PRESS RELEASE published on 05/21/2025 at 17:45, 1 year 2 months ago NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025 Compte rendu de l'assemblée générale mixte de NFL Biosciences du 21 mai 2025. Résolutions approuvées pour le développement de médicaments botaniques innovants pour traiter les addictions NFL Biosciences Médicaments Botaniques Assemblée Générale Mixte Résolutions Approuvées Addictions
BRIEF published on 05/12/2025 at 08:35, 1 year 2 months ago NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement NFL Biosciences NFL-101 Phase 3 Trials Tobacco Addiction Scientific Committee
BRIEF published on 05/12/2025 at 08:35, 1 year 2 months ago NFL Biosciences renforce son Comité Scientifique pour le développement de NFL-101 NFL Biosciences NFL-101 Phase 3 Addiction Tabac Comité Scientifique
Published on 07/21/2026 at 23:00, 1 hour 54 minutes ago Viemed Healthcare Announces Second Quarter 2026 Earnings Conference Call Details
Published on 07/21/2026 at 22:30, 2 hours 24 minutes ago Fermi Announces First Siemens Turbines Arrive at Port of Houston
Published on 07/21/2026 at 22:30, 2 hours 24 minutes ago Matador Technologies Announces Management Transition
Published on 07/21/2026 at 22:15, 2 hours 39 minutes ago Vanta Announces Updated Time for Participation in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22, 2026, at 12:00 p.m. ET
Published on 07/21/2026 at 22:00, 2 hours 54 minutes ago Redwood AI Announces Closing of $3.5 Million Private Placement
Published on 07/21/2026 at 22:30, 2 hours 23 minutes ago Strong second quarter: GEA raises full-year guidance for 2026
Published on 07/21/2026 at 22:16, 2 hours 37 minutes ago EQS-Adhoc: GEA Group Aktiengesellschaft: Preliminary numbers for Q2 2026 exceed market expectation - increase of guidance for fiscal year 2026
Published on 07/21/2026 at 18:50, 6 hours 3 minutes ago Soapeya, a DN Group AG Portfolio Company, Earns Top "Excellent" Rating from Dermatest and Proves Successful in Field Use in Ghana
Published on 07/21/2026 at 18:15, 6 hours 38 minutes ago EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/21/2026 at 18:00, 6 hours 54 minutes ago Hunyvers publie son chiffre d’affaires du troisième trimestre.
